Tranzyme GI Drug Set for Clinical Testing
Posted on: Wednesday, 11 January 2006, 15:00 CST
The FDA has given Tranzyme Pharma the all-clear to begin clinical testing of its investigational drug TZP-101 for the treatment of post-operative ileus and other gastrointestinal motility disorders.
TZP-101 is targeted at ghrelin, a peptide hormone secreted by the stomach and small intestine which plays a physiological role in the stimulation of gastrointestinal (GI) motility.
Animal data suggest that ghrelin accelerates gastric emptying, enhances small bowel transit, and reverses delayed GI transit stemming from surgery or opioid therapy.
The phase I trial will be a placebo-controlled dose escalation study designed to evaluate safety, tolerability, and pharmacodynamic parameters of TZP-101.
"The initiation of phase I studies is a significant step in the development of a mechanism-based therapeutic for the management of delayed gastric emptying," said Dr Gordana Kosutic, vice president of clinical and regulatory affairs for Tranzyme Pharma. "Disorders of delayed gastric emptying, such as post-operative ileus and gastroparesis, currently have limited therapeutic options."
Source: Datamonitor
Related Articles
- Tranzyme Pharma Initiates Dosing of Patients in a Multi-National Phase IIb Clinical Trial for the Treatment of Severe Gastroparesis
- Tranzyme Pharma Receives FDA Fast Track Designation for Its Novel Ghrelin Agonist, TZP-101, for the Treatment of Severe Gastroparesis
- Tranzyme Pharma Presents Initial Phase IIa Data for Its Novel Ghrelin Agonist, TZP-101, in Patients With Diabetic Gastroparesis
- Tranzyme Pharma Expands Clinical Program of Its Novel Ghrelin Agonist, TZP-101, to Include Patients With Gastroparesis
- Tranzyme Pharma to Present New In Vivo Data on Its Novel GI Compounds at Digestive Disease Week 2006
- New Study Supports Importance of Considering Gastric Stasis When Treating Migraine Sufferers
- Erythromycin Antagonizes the Deceleration of Gastric Emptying By Glucagon-Like Peptide 1 and Unmasks Its Insulinotropic Effect in Healthy Subjects
- The Effect of Malnutrition on Morbidity After Surgery for Chronic Pancreatitis
- Tranzyme Pharma Presents Positive Preclinical Efficacy Data for Its Lead GI Therapeutic, TZP-101; Data Presented at Digestive Disease Week 2005
- Amylin Agonists: A Novel Approach in the Treatment of Diabetes
 |
 |
User Comments (0)
RSS Feeds